Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Rosaura Esteve-Puig, PhD

    TitlePostdoctoral Scholar
    SchoolUCSF School of Medicine
    Address2340 Sutter Street
    San Francisco CA 94115
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California San FranciscoPostdoctoral ResearcherHelen Diller Family Comprehensive Cancer Center. Dermatology Department2012
      University of BarcelonaPhD in Biomedicine. Thesis title: New evasion mechanism to metabolic stress in melanomaUniversity of Barcelona- Faculty of Biology2011
      University of BarcelonaMaster's Degree, Biological and Biomedical SciencesUniversity of Barcelona. Faculty of Biology -Department of Biochemistry and Molecular Biology2007
      Vall d'Hebron Institute of ResearchPhD studentUniversity of Barcelona/Vall d'Hebron Institute of Research- Animal Model and Cancer Research2006
      Vall d'Hebron Institute of OncologyPostgraduate ResearcherGrowth Factors Laboratory2005
      University of BarcelonaBachelor of Science in Biology DegreeUniversity of Barcelona. Faculty of Biology2004
      University of BarcelonaGraduate Student ResearcherUniversity of Barcelona. Faculty of Biology -Department of Cell Biology2002

      Collapse Overview 
      Collapse Overview
      Postdoctoral researcher specializing in cancer biology since 2005.

      Pursuing an understanding of tumor molecular mechanisms with the aim of revealing novel clinical therapies.

      Expert in signal transduction pathways, protein post translational modifications, long noncoding RNAs and the molecular and cell biology of cancer with a broad range of technical experience including the recently emerged CRISPR/CAS9 system, RNA-protein interaction methods, esiRNA/shRNA technology and molecular cloning.

      Contributed missing pieces to the UV-induced DNA damage response pathway, revealed a novel mechanism for the modulation of the ERK pathway signaling by methylation, proposed a new metabolic clinical approach in cancer, and identified and characterized new kinase fusions in spitzoid melanomas.

      Collapse Interests
      Cancer, Tranlational Medicine, Signal Transduction, Cancer Cell Signaling, RAS pathway, Cancer Metabolism, noncoding RNA, Mechanisms of Cancer Drug Resistance, Tumor Biology, DNA Damage, CRISPR/CAS9-Targeted genome editing, RNA-protein interactome studies

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S, et al. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2a Kinase Levels in NRAS(Q61) Mutant Cells. J Invest Dermatol. 2016 May 29. PMID: 27251789.
        View in: PubMed
      2. Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy R, Moy A, Posch C, Monshi B, Rappersberger K, Ortiz-Urda S. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9; 7(6):7297-306. PMID: 26771141.
        View in: PubMed
      3. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20; 6(2):969-78. PMID: 25504439; PMCID: PMC4359268.
      4. Esteve-Puig R, Gil R, González-Sánchez E, Bech-Serra JJ, Grueso J, Hernández-Losa J, Moliné T, Canals F, Ferrer B, Cortés J, Bastian B, Ramón Y Cajal S, Martín-Caballero J, Flores JM, Vivancos A, García-Patos V, Recio JÁ. A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation. PLoS Genet. 2014 Oct; 10(10):e1004721. PMID: 25329316; PMCID: PMC4199501.
      5. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, Berger MF, Sparatta A, Palmedo G, Cerroni L, Busam KJ, Kutzner H, Cronin MT, Stephens PJ, Bastian BC. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014; 5:3116. PMID: 24445538; PMCID: PMC4084638.
      6. Bastian BC, Esteve-Puig R. Targeting activated KIT signaling for melanoma therapy. J Clin Oncol. 2013 Sep 10; 31(26):3288-90. PMID: 23940224.
        View in: PubMed
      7. Andreu-Pérez P, Esteve-Puig R, de Torre-Minguela C, López-Fauqued M, Bech-Serra JJ, Tenbaum S, García-Trevijano ER, Canals F, Merlino G, Avila MA, Recio JA. Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal. 2011 Sep 13; 4(190):ra58. PMID: 21917714.
        View in: PubMed
      8. Esteve-Puig R, Canals F, Colomé N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One. 2009; 4(3):e4771. PMID: 19274086; PMCID: PMC2651576.
      Rosaura's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP